TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20511610
Drug: ciclosporin added
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ciclosporin added to oral methotrexate (MTX)
Study: 12889354
Drug: Leflunomide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (20 mg/daily)
Study: 12889354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of leflunomide and methotrexate
Study: 12889354
Drug: Detralex in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detralex in combination with methotrexate
Study: 1873003
Drug: 4 to
Normalized name: LMX 4 Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 to 8 mg perindopril given once daily
Study: 1873003
Drug: 25 to
Normalized name: Hydrasyn25 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 to 50 mg captopril given twice daily
Study: 29908708
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical parameters (age, pulmonary rales, systolic blood pressure, cause of heart failure, osteoporosis, current smoking, NT‐proBNP, haemoglobin, QRS width, heart rhythm)
Study: 22614228
Drug: Quercetin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1,000 mg·d⁻¹ for 8.5 days)
Study: 20233179
Drug: Oral clotrimazole
Normalized name: clotrimazole Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clotrimazole troches 10 mg taken three times daily for 5 days
Study: 20233179
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 2 mg or intravenous midazolam 0.025 mg kg(‐1) without clotrimazole
Study: 10594437
Drug: Intubating laryngeal
Normalized name: LARYNGEAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intubating laryngeal mask using a fibreoptic bronchoscope (group L)
Study: 8210718
Drug: ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketotifen 1 mg b.i.d.
Study: 3534848
Drug: Capozide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capozide (50 mg captopril and 25 mg hydrochlorothiazide)
Study: 28039477
Drug: New risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: New risk assessment model for PSA 4-10 ng/mL
Study: 28039477
Drug: New risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: New risk assessment model for PSA 10-50 ng/mL
Study: 28039477
Drug: PSA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA alone for PSA 4-10 ng/mL
Study: 28039477
Drug: PSA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA alone for PSA 10-50 ng/mL
Study: 19456296
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitor use
Study: 20299114
Drug: Nonuse of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonuse of glycoprotein IIb/IIIa inhibitor
Study: 2939239
Drug: Latamoxef (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latamoxef (1 g intravenous injection at induction of anaesthesia)
Study: 31733781
Drug: Multimodal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal approach including patient education, manual therapy, therapeutic exercise programs, and orthotic provision
Study: 22776534
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT, 16 sessions)
Study: 22776534
Drug: Duloxetine (30-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30-60 mg/d)
Study: 22776534
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and antidepressant medication (for non-remitters)
Study: 15054512
Drug: Cariporide 20
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 20 mg
Study: 15054512
Drug: Cariporide 80
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide 80 mg
Study: 11850979
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone stimulation test
Study: 7949544
Drug: SP of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP of PBMC in patients treated with anti‐interleukin‐2‐receptor antibody, BT563 (n=8)
Study: 2884410
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at doses of 10 to 800 micrograms
Study: 2884410
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at 800 micrograms
Study: 2884410
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) with a fourth dose
Study: 29098908
Drug: Desoximetasone 0.05%
Normalized name: DESOXIMETASONE 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone 0.05% topical spray
Study: 29098900
Drug: Vehicle topical
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle topical spray
Study: 22889095
Drug: AgNano 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AgNano 10 mg/kg
Study: 22889095
Drug: AgNano 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AgNano 20 mg/kg
Study: 22889095
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg AgNano)
Study: 20214066
Drug: Flour capsule
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour capsule (Placebo)
Study: 12067837
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus lipid/heparin infusion
Study: 1898641
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) therapy
Study: 27930497
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + DM (30 mg/d)
Study: 27930497
Drug: VPA +
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA + DM (60 mg/d)
Study: 26869049
Drug: Nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 150 mg/m² (reduced to 125 mg/m² after 464 participants)
Study: 26869049
Drug: Solvent-based paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solvent-based paclitaxel 80 mg/m²
Study: 25389139
Drug: Nebulised 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised 3% hypertonic saline (HS) administered 6-hourly
Study: 19486466
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride varnish three times per school year
Study: 19486466
Drug: Varnish plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varnish plus twice‐per‐day toothbrushing and xylitol containing gummy bear snacks
Study: 10770301
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin 100 IU/kg subcutaneously twice a day)
Study: 10770301
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg every day)
Study: 8447210
Drug: P6 acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: P6 acupoint injection with 0.2 ml 50% glucose in water
Study: 8447210
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 20 micrograms/kg droperidol
Study: 30946442
Drug: Ibuprofen, 10
Normalized name: Ibuprofen, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 10 mg/kg every 6 hours for the first 9 postoperative days
Study: 30946442
Drug: Acetaminophen, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 15 mg/kg every 6 hours for the first 9 postoperative days
Study: 28138803
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment in primary care (PCP)
Study: 28138803
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment in specialist care
Study: 28138803
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment in PCP
Study: 23187164
Drug: Topical bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical bevacizumab (5 mg/mL) 4 times daily for 2 months
Study: 23187164
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear 4 times daily for 2 months
Study: 16546766
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (average of 11 individual sessions over 20 weeks)
Study: 12836580
Drug: Attachment-based family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-based family therapy (ABFT); specific treatment strategies targeting relational ruptures and rebuilding relationships; details on dosage and duration not available.
Study: 10679658
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (Arm A)
Study: 10679658
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (Arm B)
Study: 2430797
Drug: Hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 0.5% bupivacaine (2.5 ml in 8% dextrose)
Study: 2430797
Drug: Hyperbaric 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 0.5% cinchocaine (1.5 ml in 6% dextrose)
Study: 23507136
Drug: Interviewer-administered Clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered Clinical Interview Schedule (CIS-R)
Study: 18287591
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (0.05 mg/kg)
Study: 14583341
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily of purified eicosapentaenoic acid (EPA) for 6 weeks
Study: 14583341
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily of docosahexaenoic acid (DHA) for 6 weeks
Study: 11177158
Drug: 100 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/d of recombinant follicle‐stimulating hormone
Study: 11177158
Drug: 200 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU/d of recombinant follicle‐stimulating hormone
Study: 9226493
Drug: Palatable meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatable meal (Ensure, 1048 KJ, 450 ml)
Study: 25572450
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system
Study: 20048683
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g rPC daily
Study: 20048683
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g rPC daily
Study: 20048683
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g rPC daily
Study: 20048683
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g rPC daily
Study: 14562520
Drug: Interpretive short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpretive short-term group therapy
Study: 14562520
Drug: Supportive short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supportive short-term group therapy
Study: 1839644
Drug: Oral CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CBD (10 mg/kg/day for 6 weeks)
Study: 6623221
Drug: Enflurane as
Normalized name: Enflurane
DrugBank: Enflurane (DB00228)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enflurane as a volatile supplement to nitrous oxide anesthesia
Study: 6623221
Drug: Halothane as
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane as a volatile supplement to nitrous oxide anesthesia
Study: 23473527
Drug: Exenatide 5
Normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 5 μg BID for 4 weeks, then 10 μg BID for 12 weeks
Study: 22611676
Drug: Mexidol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (100 mg intramuscular for 10 days, then 125 mg orally three times a day for 20 days)
Study: 22611676
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (Diroton 5-20 mg daily, Cardiomagnyl 75 mg daily)
Study: 19256262
Drug: Creon (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creon (25 or 50% higher dose)
Study: 15094530
Drug: Individualized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized physical therapy without specific stabilizing exercises
Study: 10214426
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (treatment group)
Study: 2155958
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (2 mg, two puffs, four times per day for 12 weeks)
Study: 7428402
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vincamine
Study: 31862004
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 50 mg/kg loading dose and 30 mg/kg/h continuous maintenance infusion for 1 h (group H)
Study: 31862004
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 30 mg/kg loading dose and 15 mg/kg/h continuous maintenance infusion for 1 h (group L)
Study: 22170479
Drug: Apilimod 100
Normalized name: Apilimod
DrugBank: Apilimod (DB05611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod 100 mg/day for 4 weeks (stage 1)
Study: 22170479
Drug: Apilimod 100
Normalized name: Apilimod
DrugBank: Apilimod (DB05611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod 100 mg/day for 8 weeks (stage 2)
Study: 22170479
Drug: Apilimod 100
Normalized name: Apilimod
DrugBank: Apilimod (DB05611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod 100 mg twice a day for 8 weeks (stage 3)
Study: 15725132
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of terminal warm blood cardioplegia (TWBC)
Study: 15725132
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of terminal warm blood cardioplegia (TWBC)
Study: 12034651
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 40 mg/d
Study: 12034651
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/d plus atorvastatin or simvastatin 80 mg/d
Study: 12034651
Drug: Statin-80 (atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-80 (atorvastatin or simvastatin 80 mg/d)
Study: 9224205
Drug: Topical fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluticasone propionate (n = 10)
Study: 8017672
Drug: Propofol (6-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (6-10 mg.kg-1.h-1)
Study: 29024230
Drug: 0.05 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mol/L GABA
Study: 29024230
Drug: 0.5 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mol/L GABA
Study: 18551622
Drug: Arimoclomol at
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimoclomol at doses up to 300 mg/day
Study: 18551622
Drug: Arimoclomol at
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimoclomol at doses of 25, 50, or 100 mg three times daily
Study: 16075861
Drug: Intramuscular clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clindamycin (outpatient treatment)
Study: 16075861
Drug: Intravenous ampicillin/sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ampicillin/sulbactam (inpatient treatment)
Study: 11788637
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg T enanthate
Study: 11788637
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg T enanthate
Study: 11788637
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (control)
Study: 9872813
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 microgram twice daily via Turbohaler)
Study: 6414252
Drug: Tocainide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (750 mg bolus injection followed by oral therapy)
Study: 6414252
Drug: Lidocaine (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (conventional therapy)
Study: 31712584
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg acute dose)
Study: 24569485
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin (INS)
Study: 24569485
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral therapy (TOT) with metformin, glyburide, and pioglitazone
Study: 19013011
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (tamsulosin 0.4 mg and dutasteride 0.5 mg)
Study: 2499481
Drug: Intravenous SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous SMS 201‐995 (1.7, 0.8, 0.2, and 0.1 micrograms min‐1 for Groups A, B, C, and D respectively)
Study: 2499481
Drug: Subcutaneous SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous SMS 201‐995 (25 micrograms for Group E)
Study: 26652184
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide
Study: 27696012
Drug: Intermittent anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent anticoagulation using NOACs for 48 hours to 1 week based on daily ECG monitoring; patients transmitted daily ECGs using an iPhone-based device.
Study: 24245553
Drug: Educational course
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational course in skin-protective behaviour and written information about skin care, with access to usual care and treatment.
Study: 18567877
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg of IVIG over 2 days
Study: 16484440
Drug: NG-nitro-L-arginine methyl
Normalized name: NG-nitro-L-arginine methyl ester
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-nitro-L-arginine methyl ester (L-NAME)
Study: 16484440
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of KETO and L-NAME
Study: 16484440
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (Ringer solution)
Study: 16484440
Drug: Local heating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local heating with L-NAME
Study: 10846252
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate regimen with constant dose
Study: 10846252
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate regimen with initial loading dose
Study: 10846252
Drug: Conventional therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapeutic regimen of two capsules daily for three months
Study: 8257138
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AZT with breakfast (B)
Study: 8257138
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AZT with breakfast (B)
Study: 8257138
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AZT fasting (F)
Study: 8257138
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AZT fasting (F)
Study: 8257138
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg AZT breakfast (B)
Study: 8257138
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg AZT breakfast (B)
Study: 2931047
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin as two 250‐mg tablets
Study: 2931047
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin as one 500‐mg tablet
Study: 2931047
Drug: Ciprofloxacin solution
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin solution
Study: 27146169
Drug: Insufficient s‐25[OH]D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient s‐25[OH]D <50 nmol/L
Study: 27146169
Drug: Sufficient s‐25[OH]D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient s‐25[OH]D >80 nmol/L